Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Imatinib-Resistant CML
NCT00661180Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in chronic myelogenous leukemia (CML), sponsored by Bayer. Primary endpoint: Major Hematologic Response Rate. Started Jan 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00661180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661180.